Which is the most profitable? a. ABBV

b. LLY

c. JNJ

d. PFE

PIE (X) EVI (X) Financial ($) Company Fiscal FY1 Name Ticker Period Date EV (M) Actual FY1 FY2 Sales EBIT EBITD/ Sales (M) Bristol-Myers Squibb BMY-US 12/2021 12/2022 186,733.3 22.919. 14x 8.54x 4.03x 19.57x 9.20x 46,38 Johnson & Johnson JN-US 12/2021 12/2022 461,590.2 22.33x 16.50x 16.0 1x 4.92x 18.86x 14.48x 93,75 Roche Holding ROG-CH 12/2021 1212022 346,250.9 21.88x 17.90x 16.8 1x 5.04x 18.32% 14.57x 68,69 Pfizer PFE-US 12/2021 12/2022 304,070.5 13.45x 7.25x 9.93x 3.74x 14.62x 11.70x 81,285 AbbVie ABBV-US 12/2021 12/2022 347,587.8 24.55x 11. 17x 12.90x 6. 19% 17.60x 12.30x 56,19 Eli Lilly LLY-US 12/2021 12/2022 283,799.2 46.42x 32.83x 29.22x 10.02x 37.60x 31.20x 28,31 Novartis NOVECH 122021 12202 211,546.3 8.00x 13.67x 12.46x 4. 10x 17.73x 12.19x 51,62 Merck & Co MRKUS 12 2021 122022 228,144.2 15.51x 10.90x 11.07x 4.66x 16.69x 13.52% 48,90 Average 21.88x 14.92X 14.62% 5.34x 20.12% 14.89x Median 22. 10x 12.42X 12.68x 4.79x 18.02x 12.9 1x Margins Gross Margin (%) EBITDA Margin (%) EBIT Margin (%) Pretax Margin (%) Net Margin Company Fiscal Name Ticker Period Actual NTM Actual NTM Actual NTM Actual NTM Actual Bristol-Myers Squibb BMY-US 122021 57.7% 78.8% 43.8% 47.1% 20.6% 42.2% 17.5% 42.8% 15. Johnson & Johnson JNJ-US 12/2021 68.1% 71.1% 34.0% 36.3% 26.1% 32.0% 24.3% 33.4% 22.3 Roche Holding ROG-CH 12 2021 68.6% 76.4% 34.6% 39.9% 27.5% 34.3% 27.7% 33.0% 22.2 Pfizer PFE-US 12/2021 57.7% 68.4% 32.0% 45.9% 25.6% 43.3% 29.9% 44.9% 27.6 AbbVie ABBV-US 12/2021 69.5% 82.5% 50.3% 55.0% 35.1% 50.9% 23.1% 47.5% 20.- Eli Lilly LLY-US 12/2021 74.2% 80.2% 32.1% 36.3% 26.7% 32.4% 21.7% 32. 1% 19.1 Novartis NOVNCH 122021 69.3% 78.1% % 33.6% 35.4% 23.1% 32.4% 20.9% 27.4% 46. Merck & Co MRKUS 12/2021 72.5% 74.5% 34.5% 42.3% 27.9% 38.0% 28.4% 37.0% 25.2 Average 67.2% 76.2% 36.9% 42.3% 26.6% 38.2% 24.2% 37.3% 24.9 Median 68.9% 77.2% 34.3% 41.1% 26.4% 36.2% 23.7% 35.2% 22